Business Context and Reporting Period
Company: McKesson Corporation
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Quarter ended June 30, 2003 (First Quarter of Fiscal Year 2004)
Business Overview: McKesson operates through three primary segments: Pharmaceutical Solutions, Medical-Surgical Solutions, and Information Solutions. The company is a leading distributor of pharmaceuticals and medical products and provides information technology solutions to healthcare providers.
Key Financial Metrics
| Metric | Q1 2004 (Jun 30, 2003) | Q1 2003 (Jun 30, 2002) |
|---|---|---|
| Total Revenues | $16,524.2 million | $13,623.2 million |
| Gross Profit | $786.5 million | $750.8 million |
| Operating Income | $250.8 million | $204.5 million |
| Net Income | $155.6 million | $117.3 million |
| Diluted EPS | $0.53 | $0.39 |
| Cash from Operating Activities | $43.3 million | ($197.5 million) |
| Cash and Equivalents (End of Period) | $445.2 million | $289.8 million |
| Total Debt (Current + Long-Term) | $1,295.8 million | N/A (Balance sheet data not provided for 2002) |
| Working Capital | $3,413.2 million | N/A |
Note: Gross Profit Margin was 4.76% for Q1 2004, down from 5.51% in the prior year.
Material Changes vs. Prior Period
- Revenue Growth: Consolidated revenues increased 21% year-over-year, driven primarily by the Pharmaceutical Solutions segment (up 23%). This growth was fueled by a 48% increase in sales to customers' warehouses and a 12% increase in direct U.S. healthcare revenues.
- Profitability: Net income rose 33% to $155.6 million, and diluted earnings per share increased 36% to $0.53. Operating income grew 23%.
- Margin Compression: Despite revenue growth, gross profit margins declined by 75 basis points to 4.76%. This was attributed to a higher mix of lower-margin warehouse sales and a decrease in selling margins in the U.S. pharmaceutical distribution business, partially offset by higher margins on generic drugs.
- Cash Flow Improvement: Operating cash flow turned positive at $43.3 million, a significant improvement from a cash outflow of $197.5 million in the prior year. This was due to better inventory management and increased accounts payable supporting revenue growth.
- Acquisition: The company acquired A.L.I. Technologies Inc. for $347.0 million in cash to enhance its medical imaging solutions.
Guidance, Outlook, Risks, and Unusual Items
- Management Commentary: Management highlighted productivity improvements in back-office and field operations. The Pharmaceutical Solutions segment benefited from lower restructuring charges, though this was offset by $7.1 million in incremental product development expenses.
- Restructuring: Net restructuring charges were $1.3 million for the quarter, related to technology support consolidation and distribution center closures. Total anticipated costs for these programs are approximately $3.5 million.
- Stock Repurchases: The company repurchased 2.6 million shares for $75.3 million under a $250 million program approved in 2001.
- Legal Proceedings (Risk): Significant ongoing litigation includes shareholder suits related to the 1999 accounting restatement (HBOC). Plaintiffs have filed amended complaints seeking unspecified damages. Management states it is not feasible to predict the outcome or estimate potential losses, noting that a resolution could have a material adverse impact.
- Forward-Looking Risks: Key risks include the resolution of pending litigation, changes in U.S. healthcare reimbursement, manufacturer pricing policies, and the ability to integrate acquired businesses.
Investor Verification Checklist
- Warehouse Sales Mix: Verify the sustainability of the 48% growth in "Sales to Customers' Warehouses," which have significantly lower gross margins than direct store delivery.
- Legal Exposure: Monitor developments in the "Accounting Litigation" (Baker v. McKesson and Merrill Lynch actions) regarding the 1999 restatement, as potential settlements could be substantial.
- Working Capital Trends: Review the $3.4 billion working capital balance and the $464.5 million increase in receivables to ensure collection cycles remain stable despite revenue growth.
- Debt Covenants: Confirm continued compliance with the debt-to-capital ratio covenant (currently 21.0% vs. 56.5% limit) to avoid acceleration of debt.
- Generic Drug Pricing: Assess the impact of generic drug price declines on the Pharmaceutical Solutions segment's gross margin, which management cites as a partial offset to margin compression.